Deferasirox for Treating Iron Overload in Hereditary Hemochromatosis
Author Information
Author(s): Pradyumna Phatak, Pierre Brissot, Mark Wurster, Paul C Adams, Herbert L Bonkovsky, John Gross, Peter Malfertheiner, Gordon D McLaren, Claus Niederau, Alberto Piperno, Lawrie W Powell, Mark W Russo, Ulrich Stoelzel, Wolfgang Stremmel, Louis Griffel, Nicolas Lynch, Yiyun Zhang, Antonello Pietrangelo
Primary Institution: Rochester General Hospital
Hypothesis
Can deferasirox effectively reduce iron overload in patients with hereditary hemochromatosis?
Conclusion
Deferasirox doses of 5, 10, and 15 mg/kg/day can reduce iron burden in patients with hereditary hemochromatosis.
Supporting Evidence
- Median serum ferritin levels decreased by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively.
- More patients in the 15 mg/kg/day cohort experienced increases in liver enzymes compared to lower doses.
- Seventy-five percent of patients completed the core study, indicating good tolerability.
Takeaway
This study tested a medicine called deferasirox to help people with a condition that makes them absorb too much iron. It showed that this medicine can help lower their iron levels.
Methodology
This was an open-label, multicenter, dose-escalation study with patients receiving deferasirox at doses of 5, 10, or 15 mg/kg/day for 48 weeks.
Potential Biases
Potential conflicts of interest due to funding from Novartis and involvement of authors with the company.
Limitations
The study involved a small number of patients and many had mild iron overload.
Participant Demographics
49 Caucasian patients with hereditary hemochromatosis, predominantly male.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website